Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
McKinsey
Mallinckrodt
Johnson and Johnson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AQX-1125

See Plans and Pricing

« Back to Dashboard

What is the drug development status for AQX-1125?

AQX-1125 is an investigational drug.

There have been 6 clinical trials for AQX-1125. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Syndrome, Somatoform Disorders, and Cystitis, Interstitial. The leading clinical trial sponsors are Aquinox Pharmaceuticals (Canada) Inc., Innovaderm Research Inc., and [disabled in preview].

There are six US patents protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for AQX-1125
TitleSponsorPhase
Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain SyndromeAquinox Pharmaceuticals (Canada) Inc.Phase 2
Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction StudyAquinox Pharmaceuticals (Canada) Inc.Phase 1
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain SyndromeAquinox Pharmaceuticals (Canada) Inc.Phase 3

See all AQX-1125 clinical trials

Clinical Trial Summary for AQX-1125

Top disease conditions for AQX-1125
Top clinical trial sponsors for AQX-1125

See all AQX-1125 clinical trials

US Patents for AQX-1125

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AQX-1125   Start Trial Synthesis of a substituted indene derivative Aquinox Pharmaceuticals (Canada) Inc. (Vancouver, CA)   Start Trial
AQX-1125   Start Trial Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(aminomethyl)-7A-methyl-1-methyleneoctahy- dro-1H-inden-5-YL)-3- (hydroxymethyl)-4-methylcyclohexanol Aquinox Pharmaceuticals (Canada) Inc. (Vancouver, CA)   Start Trial
AQX-1125   Start Trial SHIP1 modulators and methods related thereto Aquinox Pharmaceuticals (Canada) Inc. (Vancouver, CA)   Start Trial
AQX-1125   Start Trial SHIP1 modulators and methods related thereto Aquinox Pharmaceuticals (Canada) Inc. (Vancouver, BC, CA)   Start Trial
AQX-1125   Start Trial SHIP1 modulators and methods related thereto Aquinox Pharmaceuticals (Canada) Inc. (Vancouver, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AQX-1125

Drugname Country Document Number Estimated Expiration Related US Patent
AQX-1125 Australia 2017209430 2036-01-20   Start Trial
AQX-1125 Israel 260169 2036-01-20   Start Trial
AQX-1125 World Intellectual Property Organization (WIPO) 2017127753 2036-01-20   Start Trial
AQX-1125 Australia 2016281658 2035-06-26   Start Trial
AQX-1125 Canada 2986790 2035-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Mallinckrodt
Dow
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.